AZD6140 - PubMed (original) (raw)
Review
AZD6140
Udaya S Tantry et al. Expert Opin Investig Drugs. 2007 Feb.
Abstract
Oral antiplatelet therapy with P2Y(12) receptor blockers (especially clopidogrel) is the current choice of treatment during acute coronary syndromes and percutaneous interventions. To address the various limitations of thienopyridine therapy (including response variability and non-responsiveness) a novel drug, AZD6140, is under clinical development. AZD6140 is an oral and reversible P2Y(12) receptor blocker that does not require hepatic conversion to an active metabolite and produces an overall superior ADP-induced platelet inhibition with less response variability than clopidogrel. It has fast onset and offset actions that may be advantageous in patients who may have to undergo immediate surgery.
Similar articles
- Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J. Kowalczyk M, et al. Med Sci Monit. 2009 Dec;15(12):MS24-30. Med Sci Monit. 2009. PMID: 19946242 Review. - Ticagrelor: a novel reversible oral antiplatelet agent.
Nawarskas JJ, Clark SM. Nawarskas JJ, et al. Cardiol Rev. 2011 Mar-Apr;19(2):95-100. doi: 10.1097/CRD.0b013e3182099d86. Cardiol Rev. 2011. PMID: 21285670 Review. - Prasugrel.
Tantry US, Bliden KP, Gurbel PA. Tantry US, et al. Expert Opin Investig Drugs. 2006 Dec;15(12):1627-33. doi: 10.1517/13543784.15.12.1627. Expert Opin Investig Drugs. 2006. PMID: 17107286 Review. - Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist.
Capodanno D, Dharmashankar K, Angiolillo DJ. Capodanno D, et al. Expert Rev Cardiovasc Ther. 2010 Feb;8(2):151-8. doi: 10.1586/erc.09.172. Expert Rev Cardiovasc Ther. 2010. PMID: 20136601 Review. - Clinical overview of promising nonthienopyridine antiplatelet agents.
Angiolillo DJ, Guzman LA. Angiolillo DJ, et al. Am Heart J. 2008 Aug;156(2 Suppl):S23-8. doi: 10.1016/j.ahj.2008.06.006. Am Heart J. 2008. PMID: 18657683 Review.
Cited by
- Development of selective agonists and antagonists of P2Y receptors.
Jacobson KA, Ivanov AA, de Castro S, Harden TK, Ko H. Jacobson KA, et al. Purinergic Signal. 2009 Mar;5(1):75-89. doi: 10.1007/s11302-008-9106-2. Epub 2008 Jul 4. Purinergic Signal. 2009. PMID: 18600475 Free PMC article. - Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents.
Testa L, Biondi Zoccai GG, Valgimigli M, Latini RA, Pizzocri S, Lanotte S, Laudisa ML, Brambilla N, Ward MR, Figtree GA, Bedogni F, Bhindi R. Testa L, et al. Adv Hematol. 2010;2010:595934. doi: 10.1155/2010/595934. Epub 2010 Dec 5. Adv Hematol. 2010. PMID: 21151515 Free PMC article. - Application of triazoles as bioisosteres and linkers in the development of microtubule targeting agents.
Malik MS, Ahmed SA, Althagafi II, Ansari MA, Kamal A. Malik MS, et al. RSC Med Chem. 2020 Jan 29;11(3):327-348. doi: 10.1039/c9md00458k. eCollection 2020 Mar 1. RSC Med Chem. 2020. PMID: 33479639 Free PMC article. Review. - Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.
Siller-Matula JM, Krumphuber J, Jilma B. Siller-Matula JM, et al. Br J Pharmacol. 2010 Feb 1;159(3):502-17. doi: 10.1111/j.1476-5381.2009.00555.x. Epub 2009 Dec 24. Br J Pharmacol. 2010. PMID: 20050853 Free PMC article. Review. - P2Y nucleotide receptors: promise of therapeutic applications.
Jacobson KA, Boeynaems JM. Jacobson KA, et al. Drug Discov Today. 2010 Jul;15(13-14):570-8. doi: 10.1016/j.drudis.2010.05.011. Epub 2010 Jun 2. Drug Discov Today. 2010. PMID: 20594935 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical